RxDoctor Payments Data

Mariel Miller

Acute Care · Birmingham, ALNPI 1245707629

Payments from drug & device makers

$1,763in general payments, 2019–2025

Across 113 payments — averaging $15.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$384
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$363
  • E.r. Squibb & Sons, L.L.C.$209
  • Pfizer$195
  • Novartis$108
  • Abbott$74
  • plus $430 from 15 others

What the payments were for

  • Food & beverage$1,763100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,763 in reported general payments places this provider in the 75th percentile of 711 acute care providers in Alabama.

See all acute care providers in Alabama

Medicare billing

Part B allowed, 2024
$42,580
Medicare patients
274
Services billed
719

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide371$381,064
MounjaroTirzepatide51$60,416
FarxigaDapagliflozin Propanediol75$52,161
EliquisApixaban42$38,830
EntrestoSacubitril/Valsartan23$21,191
WegovySemaglutide15$19,943
JardianceEmpagliflozin13$15,608
Repatha SureclickEvolocumab12$12,588
XareltoRivaroxaban16$12,330
Ranolazine ErRanolazine24$2,539
Metoprolol Succinate92$1,017
Olmesartan Medoxomil64$808
Bupropion XlBupropion Hcl23$752
Pravastatin Sodium22$634
ClopidogrelClopidogrel Bisulfate31$458

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Wegovy$384$401,007386 claims
Lilly USA, LLCMounjaro$16$60,41651 claims
AstraZenecaFarxiga$28$52,16175 claims
PfizerEliquis$195$38,83042 claims
NovartisEntresto$108$21,19123 claims
Boehringer IngelheimJardiance$51$15,60813 claims
Johnson & JohnsonXarelto$20$12,33016 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 711 acute care providers in Alabama.

Other acute care in Birmingham

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →